Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
AI-Generated Summary
Servier, an international pharmaceutical group, has acquired KER-0193 from Kaerus Bioscience, a potential treatment for Fragile X syndrome (FXS). FXS is the leading genetic cause of autism spectrum disorder, for which there are currently no approved treatments. This acquisition, valued up to $450 million, significantly bolsters Servier's neurology pipeline and commitment to rare disease therapies, with Phase 2 trials planned for 2026.
In a nutshell
This acquisition marks a significant advancement in addressing the critical unmet medical need for patients with Fragile X syndrome, offering hope for a novel therapeutic option where none currently exist. It also underscores Servier's strategic focus on expanding its presence in the neurology rare disease sector.
Source: PR Newswire UK
